Document is current
Any future updates will be listed below
-
Authors
Westra, Jelmer
Eftekhari, Ashkan
Renkens, Mick
Mejía-Rentería, Hernán
Sejr-Hansen, Martin
Stegehuis, Valérie
Holm, Niels Ramsing
de Winter, Robert-Jan
Piek, Jan J.
Escaned, Javier
Wykrzykowska, J. J.
Christiansen, Evald Høj
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01813435 at ClinicalTrials.govDocuments that mention this clinical trial
Dual antiplatelet therapy for secondary prevention of coronary artery disease
https://doi.org/10.1136/openhrt-2017-000651
Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention
https://doi.org/10.1161/circinterventions.120.009177
Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting
https://doi.org/10.1136/heartjnl-2015-309022
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54
https://doi.org/10.1136/heartjnl-2015-307858
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events
https://doi.org/10.1161/circoutcomes.120.006660
The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial
https://doi.org/10.1007/s00392-020-01604-1
Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial
https://doi.org/10.1186/s12933-020-01153-x
Coronary revascularisation in the elderly
https://doi.org/10.1136/heartjnl-2015-308999
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) (Results)
https://doi.org/10.1136/bmjopen-2018-026053
Characterization of quantitative flow ratio and fractional flow reserve discordance using doppler flow and clinical follow-up
https://doi.org/10.1007/s10554-022-02522-1
Parsimonious versus extensive bleeding score: can we simplify risk stratification after percutaneous coronary intervention and reduce bleeding events by de-escalation of the antiplatelet strategy?
https://doi.org/10.1136/openhrt-2024-003083
Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence
https://doi.org/10.1016/j.clinthera.2016.02.016
- License Information
-
More Information
Article History
Received: 1 November 2021
Accepted: 4 January 2022
First Online: 18 January 2022
Declarations
:
: Dr. Mejia-Renteria has received consultancy fees from Medis Medical Imaging and speaker fees from Philips and Abbott out of the submitted work. Dr. Evald Christiansen received research grants from Medis and Philips/Volcano to his institution outside of the submitted work. The remaining authors have no disclosures to report.
